NASDAQ:TRDA Entrada Therapeutics Q2 2026 Earnings Report $7.70 +0.43 (+5.97%) As of 03:01 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Entrada Therapeutics EPS ResultsActual EPS-$1.01Consensus EPS -$0.97Beat/MissMissed by -$0.04One Year Ago EPSN/AEntrada Therapeutics Revenue ResultsActual Revenue$0.90 millionExpected Revenue$2.32 millionBeat/MissMissed by -$1.43 millionYoY Revenue GrowthN/AEntrada Therapeutics Announcement DetailsQuarterQ2 2026Date8/5/2026TimeBefore Market OpensConference Call DateWednesday, August 5, 2026Conference Call Time7:00AM ETUpcoming EarningsEntrada Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Entrada Therapeutics Earnings HeadlinesQ3 EPS Estimate for Entrada Therapeutics Lowered by AnalystAugust 14, 2026 | americanbankingnews.comEntrada Therapeutics (NASDAQ:TRDA) Major Shareholder Ventures L.P. 5Am Sells 52,317 SharesAugust 11, 2026 | americanbankingnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.August 19 at 1:00 AM | Profits Run (Ad)Entrada Therapeutics (NASDAQ:TRDA) Director Kush Parmar Sells 52,317 SharesAugust 11, 2026 | americanbankingnews.comEntrada Therapeutics (NASDAQ:TRDA) Director Kush Parmar Sells 92,444 Shares of StockAugust 11, 2026 | americanbankingnews.comEntrada Therapeutics Reports Second Quarter 2026 Financial ResultsAugust 5, 2026 | finance.yahoo.comSee More Entrada Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Entrada Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entrada Therapeutics and other key companies, straight to your email. Email Address About Entrada TherapeuticsEntrada Therapeutics (NASDAQ:TRDA) (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs. The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity. Lead programs target lysosomal storage disorders and neuromuscular diseases, with preclinical candidates optimized for tissue tropism and intracellular uptake. Entrada’s technology is designed to be modular, allowing for potential application across multiple therapeutic areas. Founded in Cambridge, Massachusetts, Entrada leverages a team with expertise in protein engineering, cell biology and drug delivery. The company serves patients globally by pursuing regulatory filings in key markets and collaborating with academic partners and contract development organizations. Through continued platform development and strategic partnerships, Entrada seeks to bring novel intracellular therapies from lab to clinic.View Entrada Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Target Is Winning Shoppers Back—Can the Rally Reach $180?Why Lowe’s Could Be a Bargain Before Housing RecoversIs Apple’s AI Strategy Smarter Than Skeptics Think?IonQ’s Space Contract Points to a New Frontier for Quantum InvestorsQuantum Stocks Are Starting to Choose Sides: Should Investors Do the Same?AeroVironment Hit a Bottom in Q2—Can It Take Flight in Q3?Tesla's Cybercab Launch Could Reshape Margins for Uber and Lyft Upcoming Earnings NetEase (8/20/2026)Alibaba Group (8/20/2026)Ross Stores (8/20/2026)Walmart (8/20/2026)Deere & Company (8/20/2026)PDD (8/24/2026)Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Heico (8/25/2026)Intuit (8/25/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
